SCHEMBL25921866

SCHEMBL25921866

CN1C(=O)CSc2ccc(C(=O)Nc3ccc(S(=O)(=O)N4CCCCC4)cc3)cc21

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ CYP2C9 P11712 1/20 0.58
▸ USP2 O75604 3/20 0.57
▸ MAPT P10636 3/20 0.57
▸ GAA P10253 3/20 0.57
▸ POLB P06746 1/20 0.57
▸ CTDSP1 Q9GZU7 1/20 0.57
▸ KMT2A Q03164 7/20 0.56
▸ ALDH1A1 P00352 6/20 0.56
▸ MEN1 O00255 5/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ TSHR P16473 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ LMNA P02545 3/20 0.55
▸ KDM4E B2RXH2 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30270587 1.00 CYP1A2 (0.58) CYP1A2CYP3A4CYP2C9USP2MAPT
SCHEMBL25922344 0.89 CYP1A2 (0.56) CYP1A2CYP3A4CYP2C9USP2MAPT
SCHEMBL25933155 0.89 MEN1 (0.56) MAPTPOLBKMT2AALDH1A1MEN1
SCHEMBL25922340 0.88 CTDSP1 (0.64) CYP1A2CYP3A4CYP2C9USP2MAPT
SCHEMBL24124800 0.88 MAPT (0.62) USP2MAPTGAAKMT2AALDH1A1
SCHEMBL25921176 0.88 CNR2 (0.52) USP2MAPTPOLBKMT2AALDH1A1
SCHEMBL25921173 0.87 MAPT (0.53) USP2MAPTPOLBKMT2AALDH1A1
SCHEMBL24125084 0.87 MAPT (0.61) USP2MAPTGAAKMT2AALDH1A1
SCHEMBL25922300 0.87 CTDSP1 (0.61) CYP1A2CYP3A4CYP2C9USP2MAPT
SCHEMBL25930932 0.86 MAPT (0.52) USP2MAPTPOLBCTDSP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 CYP1A2 4227/4885CYP3A4 4275/4885CYP2C9 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback